A patient ((b)(6)) was enrolled in the post-approval coaptite injectable implant study for stress urinary incontinence.The patient was injected with a total of 3.0ml of coaptite, lots 1033386, 1032766, 1032765 on (b)(6) 2012.On (b)(6) 2013 a urine culture was performed and the patient was diagnosed with a urinary tract infection.The patient was treated with keflex 500mg bid x 7 days starting on (b)(6) 2013.As of (b)(6) 2013 the event was resolved.The physician assessed the event as mild and possibly device related.
|